Cooperation with the Commission and willingness to comply with the Act
82. Cooperation with the Commission is relevant to, and may mitigate, the penalty imposed by the Court: Australian Competition and Consumer Commission v Tyco Australia Pty Ltd (2000) ATPR 41‑760 at 40,961; Australian Competition and Consumer Commission v SIP Australia Pty Limited (1999) ATPR 41‑702 at 43,005-43,006; Australian Competition and Consumer Commission v J McPhee & Son (Australia) Pty Ltd (supra) at 40,892; Trade Practices Commission v CC (New South Wales) (supra) at 42,725. Considerable evidence was given in relation to this issue - perhaps more than for any other relevant factor. In short, although there was communication and provision of some information by Dermalogica to the Commission, the level of cooperation and compliance were in dispute.
83. It is useful to set out a short sequence of events in relation to the complaints, the investigation and the cooperation given by Dermalogica. At the time of the contravening conduct, Dermalogica had no compliance program, indeed its policy can be evinced from its letter dated 16 September and web policies.
84. Dermalogica submitted that it sought legal advice as to whether it could restrain stockists from selling below the prices Dermalogica recommended, and in particular whether they could refuse supply to achieve this result. However the date upon which the advice had been sought was in issue. Dermalogica's actual request for advice was withheld on the basis of legal professional privilege, but the tendered documents (including the letter of advice consequently provided by Dermalogica's initial solicitors, Steingold Abel) indicated that Dermalogica had sought advice. I accept the evidence of Ms Cassie that Dermalogica sought that advice on 16 September 2002, the same day that the letters discussed at par [19] above were sent to Fatal Attraction and Café Beauty.
85. Dermalogica received its advice from Steingold Abel on 26 September 2002, which summed up the provisions of the Act and concluded by suggesting that 'You may wish to write to [your stockists] to request that they sell at the recommended retail price, but you should also state that the price is not obligatory and also ensure that the request is not framed in such a way as to be taken [as] an attempt to induce the stockist not selling [sic] below the recommended retail price.'
86. Dermalogica became aware of Fatal Attraction's complaint and of the Commission's investigation the following day. By a letter of 27 September 2002, the Commission first advised Dermalogica of a complaint made by Fatal Attraction in respect of Dermalogica's conduct and requested that Dermalogica provide information to the Commission in relation to that complaint. Ms Cassie stated that Dermalogica immediately contacted Steingold Abel. On 30 September 2002, in a telephone conversation between Ms Cassie and Mr Mark Schramm, an officer of the Commission, Ms Cassie indicated she would provide the Commission with the information requested in its letter of 27 September.
87. On 3 October Steingold Abel wrote to the Commission to indicate that the firm had been consulted by Dermalogica to obtain their 'advice as to what action it could take (if any) to prevent stockists from selling products at less than the recommended retail price.' Upon provision of the requested advice, Steingold Abel said that Dermalogica contacted its agents and servants and instructed them not to take any action in relation to any stockists that were discounting prices. It requested the Commission to indicate that no further action would be taken.
88. The Commission responded on 3 October, noting that Steingold Abel's letter of 3 October appeared to suggest that Dermalogica was not willing to provide the information Ms Cassie had said the company would provide.
89. On 11 October Steingold Abel responded that Dermalogica had not agreed to provide all the information requested by the Commission. However, the 11 October letter provided information on a number of matters including Dermalogica's provision to its stockists of price lists and policies, approximate numbers of its stockists throughout Australia at that time, and Dermalogica's lack of an internal Trade Practices Act compliance program. Steingold Abel said that where Dermalogica had not provided the information the Commission had requested, alternative material could be provided.
90. The Commission wrote to Steingold Abel on 15 October (presumably not in response to the above letter, which was apparently received by the Commission on 17 October) further requesting information on a range of matters including those discussed in the 11 October letter from Steingold Abel.
91. On 5 November 2002 Dermalogica changed its website by deleting both those sections in which it was asserted that Dermalogica 'strongly discouraged' deviation from Dermalogica's suggested retail prices. There is no evidence that the assertion by Dermalogica that violation of any of the web policies could or would lead to cancellation of account, was deleted. I consider that the intention behind making only the former deletion but not the latter appears to have been to comply with the Act, while retaining the threat of account cancellation (among other things) as a sanction for breach of those web guidelines dealing with matters other than resale price maintenance, such as use of Dermalogica trademarks and images.
92. On 6 November KPMG Legal, who in the interim had been engaged to advise Dermalogica, responded on behalf of Dermalogica. KPMG Legal dealt with a wide range of matters. It is not necessary to discuss them in any detail save to say that the letter mentioned the complaints Dermalogica had received from stockists about the discounted internet sales, the sending of the 16 September letter, a change in the Dermalogica website content and that Dermalogica would welcome the opportunity to discuss the matters and the company's policies and procedures more fully with the Commission.
93. On 6 November 2002 Fatal Attraction and Café Beauty received a letter from Ms Cassie retracting the requests made in the letter of 16 September 2002 and acknowledging that in accordance with legal requirements, 'Dermalogica cannot and does not control or attempt to influence in any way or by any means the prices charged by its stockists or their advertised prices.' ("the retraction letter"). The content of the circular letter to all Dermalogica stockists was similar to the content of the retraction letters, although its stated object was merely to 'clarify' Dermalogica's position on both the issues of discounted Internet sales specifically and pricing policy generally. Dermalogica sent a similar email to its sales personnel, but it also instructed that where stockists complained about the prices of other stockists, the sales personnel should inform the complaining stockist that Dermalogica does not control or attempt to influence resale prices.
94. The Commission submitted that the delay of approximately six weeks between the 16 September letters and their retraction evidenced the company's lax attitude to compliance with the Act. Dermalogica submitted that, from the pattern of correspondence between Dermalogica's legal advisors and the Commission, the inference should be drawn that the delay was due to Dermalogica's legal advisors obtaining instructions, giving advice and cooperating with the Commission.
95. I am disposed to accept Dermalogica's explanation for its delay. Dermalogica was engaged in consulting with its legal advisors and, upon consultations being substantially completed, it immediately set about rectifying the situation. Even while those consultations were taking place, Dermalogica and its legal advisors were engaged in the process of cooperating with the Commission. In my view, Dermalogica's explanations for its delay are acceptable. It legitimately reserved its rights.
96. Further, I note that Dermalogica complied with the Commission's request insofar as it volunteered information to the Commission in relation to other potential breaches of the Act. Notwithstanding the delay and some slight confusion at the outset as to whether the requested information was forthcoming, in my view the evidence indicates that Dermalogica cooperated with the Commission adequately.
97. Similarly, I am satisfied that the changes made to the website on 5 November, the retraction letters of 6 November and Dermalogica's communication to its sales staff of the Act's implications for Dermalogica's pricing policy all indicate a reasonable attitude towards compliance with the Act.
98. However, I am not satisfied that Dermalogica has taken sufficient steps towards implementing an adequate program of compliance and control since it became aware that its conduct might have been in contravention of the Act. Since early November 2002, Ms Cassie had been designated as Dermalogica's 'compliance officer'. However, under cross‑examination, it became apparent that Ms Cassie had no significant awareness of the stipulations of the Act other than insofar as they had already been invoked against Dermalogica. This is but one example of a general ignorance of the Act within Dermalogica's corporate culture. Ms Cassie indicated that in early 2003 Dermalogica staff were treated to a trade practices training course over part of a day. But that, in my view, is a far cry from efforts which would encourage the sort of pervasive awareness of and respect for the Act which the courts have treated as a factor mitigating the appropriate penalty.
99. Finally, it is perhaps appropriate to note at this point that Dermalogica has not previously contravened the Act. As has been demonstrated recently in Australian Competition and Consumer Commission v George Weston Foods Ltd (2004) 210 ALR 486, a record of prior contraventions of the Act might become a factor raising the appropriate pecuniary penalty very significantly in a particular case. But this does not apply to Dermalogica.